cervical cancer– tag –

[FDA Approval Alert] Tisotumab vedotin-tftv by Seagen and Genmab approved for recurrent/metastatic cervical cancer (June 21, 2025) On June 21, 2025, the U.S. FDA approved Tisotumab vedotin-tftv (Tivdak) for the treatment of recurrent or ...